Reducing cannabis use to improve daily functioning.
Official title: Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use
Run by Medical University of South Carolina · NCT07218471 · Data updated 2026-11-12
This program will try an 8-week combination of motivational interviewing, computerized CBT (CBT4CBT), and small financial rewards to help adults with cannabis use disorder cut back on cannabis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 176 (estimated) |
| Sponsor | Medical University of South Carolina Academic / other |
| Locations | 1 site (Charleston, South Carolina) |
| Status | Recruiting |
| Started | March 13, 2026 |
| Main results expected | September 15, 2029 |
| Study ends | January 30, 2030 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT07218471 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a DSM-5 diagnosis of cannabis use disorder, a baseline urinary cannabinoid level ≥50 ng/mL, and willingness to try reducing cannabis are the intended participants.
✕Probably not a fit
People who are pregnant or breastfeeding, have serious medical or psychiatric conditions that could worsen with reduction, use cannabis only for medical reasons, or cannot complete consent or study procedures may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults diagnosed with DSM-5 cannabis use disorder who have a baseline urinary cannabinoid level ≥50 ng/mL will take part in an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and contingency management with financial incentives tied to reduced urinary cannabinoids. Participants will provide urine samples to document change in cannabinoid levels and complete measures of cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life. The protocol requires an intake visit and excludes people with serious medical or psychiatric conditions, pregnancy or breastfeeding, or those using cannabis solely for medical purposes. The study is conducted at the Medical University of South Carolina and uses objective biologic testing alongside behavioral treatment modules.
Why it matters
Potential benefit: If successful, the approach could help people reduce cannabis use and improve sleep, thinking, and overall quality of life.
How similar studies have gone: Previous studies using motivational interviewing, computerized CBT, and contingency management have shown benefits for substance use disorders and some success in reducing cannabis use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18+ * Urinary cannabinoid level ≥ 50 ng/mL * DSM-5 diagnosis of CUD (mild, moderate, or severe) * Willingness to attempt cannabis reduction * Completion of Intake Visit Exclusion Criteria: * Serious medical/psychiatric conditions * Pregnancy or breastfeeding * Use of cannabis in past 30 days was for medical purposes only * Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition * Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz
Where it's running
-
Medical University of South Carolina
Charleston, South Carolina, United States Recruiting
Study contacts
- Principal investigator: Rachel Tomko, PhD. — Medical University of South Carolina
- Study coordinator: Rachel Tomko, PhD
- Email: tomko@musc.edu
- Phone: (843) 792-5447
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can tACS modulate motivation and reward signals in cannabis use disorder and depression
We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.
-
Sex differences in how cannabis affects people who regularly use it
This Phase 2 trial tests whether men and women who use cannabis several days a week respond differently to THC versus placebo.
-
Semaglutide for cannabis use disorder: see if a medicine helps reduce use
This study tests whether weekly injections of semaglutide can help adults with cannabis use disorder reduce their cannabis use compared with placebo.
-
Brain imaging to predict teens' response to cannabis treatment
This project will test whether teens' brain activity during a learning task can predict how well 14–17-year-olds do in a 10-week virtual reward program to reduce cannabis use.
-
Home-based brain stimulation with guided mindfulness for cannabis use disorder
This project tests whether daily at-home mild brain stimulation plus guided mindfulness can help adults with cannabis use disorder reduce or stop their cannabis use.
-
12-week aerobic exercise program for people using cannabis
This program will try a 12-week indoor cycling regimen to see if regular exercise reduces cannabis dependence and the severity of cannabis use disorder in adults aged 18–40.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.